CLPT (ClearPoint Neuro) Cyclically Adjusted FCF per Share: $-0.79 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLPT ClearPoint Neuro Inc CLPT
63 GF Score
Price $15.16
GF Value $14.14
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is ClearPoint Neuro Cyclically Adjusted FCF per Share?

ClearPoint Neuro CLPT +1.95% 63 Cyclically Adjusted FCF per Share is $-0.79 as of Jun. 2026. GuruFocus rates CLPT with a GF Score™ of 63/100 and a GF Value™ of $14.14 (Fairly Valued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

ClearPoint Neuro's adjusted free cash flow per share for the three months ended in Jun. 2026 was $-0.240. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.79 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 28.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of ClearPoint Neuro was 28.90% per year. The lowest was 22.90% per year. And the median was 25.90% per year.

As of today (2026-08-12), ClearPoint Neuro's current stock price is $15.16. ClearPoint Neuro's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was $-0.79. ClearPoint Neuro's Cyclically Adjusted Price-to-FCF of today is .


ClearPoint Neuro  (NAS:CLPT) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


ClearPoint Neuro Cyclically Adjusted FCF per Share Related Terms


ClearPoint Neuro Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for ClearPoint Neuro's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ClearPoint Neuro Cyclically Adjusted FCF per Share Chart

ClearPoint Neuro Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.14 -2.59 -2.00 -1.44 -0.93

ClearPoint Neuro Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.09 -0.98 -0.93 -0.87 -0.79

CLPT vs SI, PACB, DCTH: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, ClearPoint Neuro's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ClearPoint Neuro Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ClearPoint Neuro's Cyclically Adjusted Price-to-FCF falls into.


CLPT
63GF Score
ClearPoint Neuro Inc CLPT
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ClearPoint Neuro Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ClearPoint Neuro's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.24/333.9520*333.9520
=-0.240

Current CPI (Jun. 2026) = 333.9520.

ClearPoint Neuro Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.509 241.428 -0.704
201612 -0.308 241.432 -0.426
201703 -0.372 243.801 -0.510
201706 -0.193 244.955 -0.263
201709 -0.163 246.819 -0.221
201712 -0.163 246.524 -0.221
201803 -0.185 249.554 -0.248
201806 -0.104 251.989 -0.138
201809 -0.090 252.439 -0.119
201812 -0.053 251.233 -0.070
201903 -0.055 254.202 -0.072
201906 -0.066 256.143 -0.086
201909 -0.069 256.759 -0.090
201912 -0.031 256.974 -0.040
202003 -0.180 258.115 -0.233
202006 -0.110 257.797 -0.142
202009 -0.087 260.280 -0.112
202012 -0.144 260.474 -0.185
202103 -0.115 264.877 -0.145
202106 -0.171 271.696 -0.210
202109 -0.152 274.310 -0.185
202112 -0.169 278.802 -0.202
202203 -0.188 287.504 -0.218
202206 -0.211 296.311 -0.238
202209 -0.183 296.808 -0.206
202212 -0.135 296.797 -0.152
202303 -0.237 301.836 -0.262
202306 -0.226 305.109 -0.247
202309 -0.082 307.789 -0.089
202312 -0.055 306.746 -0.060
202403 -0.151 312.332 -0.161
202406 -0.097 314.175 -0.103
202409 -0.043 315.301 -0.046
202412 -0.045 315.605 -0.048
202503 -0.229 319.799 -0.239
202506 -0.094 322.561 -0.097
202509 -0.117 324.800 -0.120
202512 -0.420 324.054 -0.433
202603 -0.291 330.213 -0.294
202606 -0.240 333.952 -0.240

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.79 mean?
ClearPoint Neuro (CLPT) has a Cyclically Adjusted FCF per Share of $-0.79 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ClearPoint Neuro and its competitors.
Is ClearPoint Neuro's Cyclically Adjusted FCF per Share too high?
ClearPoint Neuro's current Cyclically Adjusted FCF per Share is $-0.79. Overall, ClearPoint Neuro has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ClearPoint Neuro's Cyclically Adjusted FCF per Share compare to SI and PACB?
ClearPoint Neuro's Cyclically Adjusted FCF per Share of $-0.79 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ClearPoint Neuro and its competitors. ClearPoint Neuro's current Cyclically Adjusted FCF per Share is $-0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClearPoint Neuro stock overvalued right now?
Based on GuruFocus' analysis, ClearPoint Neuro (CLPT) is currently considered Fairly Valued. The stock's GF Value™ is $14.14, compared to a current price of $15.16 — trading 7.2% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-0.79. ClearPoint Neuro's overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For ClearPoint Neuro (CLPT), the current Cyclically Adjusted FCF per Share is $-0.79 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ClearPoint Neuro (CLPT) Overvalued in 2026?

Based on GuruFocus' analysis, ClearPoint Neuro stock appears to be overvalued. The current stock price of $15.16 is trading 7.2% above its estimated GF Value™ of $14.14. GuruFocus considers ClearPoint Neuro to be Fairly Valued.

Key valuation signals for CLPT:

  • Cyclically Adjusted FCF per Share: $-0.79
  • GF Value™: $14.14 vs. price of $15.16 (7.2% above fair value)
  • GF Score™: 63/100 with 8 warning signs

No single metric tells the full story. See the CLPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ClearPoint Neuro Business Description

Address 120 S. Sierra Avenue, Suite 100, Solana Beach, CA, USA, 92075
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
63GF Score

Get the complete analysis for CLPT

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.16
Price
$14.14
GF Value